BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 14657001)

  • 1. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
    FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
    Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
    J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
    Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
    Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
    Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro.
    Magnusson PU; Looman C; Ahgren A; Wu Y; Claesson-Welsh L; Heuchel RL
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2142-9. PubMed ID: 17656670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
    Inai T; Mancuso M; Hashizume H; Baffert F; Haskell A; Baluk P; Hu-Lowe DD; Shalinsky DR; Thurston G; Yancopoulos GD; McDonald DM
    Am J Pathol; 2004 Jul; 165(1):35-52. PubMed ID: 15215160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
    J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
    Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
    Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy.
    Wilkinson-Berka JL; Babic S; De Gooyer T; Stitt AW; Jaworski K; Ong LG; Kelly DJ; Gilbert RE
    Am J Pathol; 2004 Apr; 164(4):1263-73. PubMed ID: 15039215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation.
    Darden J; Payne LB; Zhao H; Chappell JC
    Angiogenesis; 2019 Feb; 22(1):167-183. PubMed ID: 30238211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.
    Jo N; Mailhos C; Ju M; Cheung E; Bradley J; Nishijima K; Robinson GS; Adamis AP; Shima DT
    Am J Pathol; 2006 Jun; 168(6):2036-53. PubMed ID: 16723717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia paradoxically inhibits the angiogenic response of isolated vessel explants while inducing overexpression of vascular endothelial growth factor.
    Aplin AC; Nicosia RF
    Angiogenesis; 2016 Apr; 19(2):133-46. PubMed ID: 26748649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
    Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
    Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.